Shares of Minerva Neurosciences, Inc (NASDAQ:NERV) have been assigned a consensus rating of “Hold” from the six analysts that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $16.00.
A number of analysts recently issued reports on NERV shares. Zacks Investment Research upgraded Minerva Neurosciences from a “hold” rating to a “buy” rating and set a $7.75 price target for the company in a report on Wednesday, September 13th. ValuEngine lowered Minerva Neurosciences from a “sell” rating to a “strong sell” rating in a report on Sunday.
Shares of Minerva Neurosciences (NERV) opened at $6.15 on Thursday. The stock has a market capitalization of $238.01, a P/E ratio of -5.54 and a beta of 1.53. Minerva Neurosciences has a twelve month low of $4.80 and a twelve month high of $12.60.
In other Minerva Neurosciences news, CFO Geoff Race sold 5,829 shares of the company’s stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $5.79, for a total transaction of $33,749.91. Following the completion of the sale, the chief financial officer now owns 197,698 shares in the company, valued at $1,144,671.42. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In the last 90 days, insiders have sold 12,590 shares of company stock valued at $73,073. 21.60% of the stock is owned by company insiders.
A number of institutional investors have recently bought and sold shares of the business. ProShare Advisors LLC lifted its holdings in Minerva Neurosciences by 1.4% during the second quarter. ProShare Advisors LLC now owns 21,063 shares of the biopharmaceutical company’s stock worth $186,000 after buying an additional 297 shares during the period. Nationwide Fund Advisors increased its position in shares of Minerva Neurosciences by 14.2% during the second quarter. Nationwide Fund Advisors now owns 13,005 shares of the biopharmaceutical company’s stock worth $115,000 after purchasing an additional 1,616 shares in the last quarter. California State Teachers Retirement System increased its position in shares of Minerva Neurosciences by 7.5% during the second quarter. California State Teachers Retirement System now owns 44,537 shares of the biopharmaceutical company’s stock worth $394,000 after purchasing an additional 3,100 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Minerva Neurosciences by 54.6% during the second quarter. Russell Investments Group Ltd. now owns 15,794 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 5,579 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in shares of Minerva Neurosciences by 38.8% during the second quarter. The Manufacturers Life Insurance Company now owns 22,359 shares of the biopharmaceutical company’s stock worth $198,000 after purchasing an additional 6,251 shares in the last quarter. Institutional investors own 73.68% of the company’s stock.
About Minerva Neurosciences
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.